Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P230011/S006

TruSight Oncology Comprehensive

Illumina, Inc. · Decision date Aug 14, 2026

FDA DECISIONP230011/S006

What did the FDA approve?

FDA records P230011/S006 as a supplement to PMA P230011, with the supplement type “Panel Track”. The recorded decision is approval, dated Aug 14, 2026.

FDA approval order statement

Approval to expand the intended use of the TruSight Oncology Comprehensive to include a companion diagnostic indication to identify RET fusions in thyroid cancer (TC) patients and RET small DNA variant mutations in medullary thyroid cancer (MTC) patients who may benefit from treatment with RETEVMO (selpercatinib).
Regulatory pathway
PMA supplement
Supplement type
Panel Track
Clinical specialty
Pathology
Decision date
Aug 14, 2026
FDA change category
Labeling Change - Indications/instructions/shelf life/tradename

FDA source record

Regulatory record facts

Identifier
P230011/S006
Regulatory pathway
PMA supplement
Product code
PQP
Decision code
APPR
Decision date
Aug 14, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Next generation sequencing oncology panel, somatic or germline variant detection system.

Product code
PQP
FDA device class
3

For the original device and its historical approval scope, see PMA P230011. Subsequent supplements may change the device or its indications.

FDA decision timeline

  1. P230011 · Original PMA

    TruSight Oncology Comprehensive

  2. P230011/S004 · Related supplement

    TruSight Oncology Comprehensive

  3. P230011/S005 · Related supplement

    TruSight Oncology Comprehensive

  4. P230011/S006 received

    Application receipt date recorded by FDA.

  5. P230011/S007 · Related supplement

    TruSight Oncology Comprehensive

  6. P230011/S002 · Related supplement

    TruSight Oncology Comprehensive

  7. P230011/S006 · FDA decision

    Panel Track

  8. P230011/S008 · Related supplement

    TruSight Oncology Comprehensive

Timeline entries are records held by MedtechLedger for P230011. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P230011

Product / regulatory recordCompanyPathwayDecision dateSource
Illumina, Inc.PMA approvalAug 21, 2024FDA
Illumina, Inc.PMA supplementSep 5, 2025FDA
Illumina, Inc.PMA supplementSep 19, 2025FDA
Illumina, Inc.PMA supplementApr 23, 2026FDA
Illumina, Inc.PMA supplementJun 26, 2026FDA
Illumina, Inc.PMA supplementSep 4, 2026FDA

Explore the linked device profile

Other records with product code PQP

Product / regulatory recordCompanyPathwayDecision dateSource
Life Technologies CorporationPMA supplementNov 4, 2026FDA
xT CDxP210011/S006
Tempus AI, Inc.PMA supplementOct 23, 2026FDA
MI Cancer SeekP240010/S007
Caris Life SciencesPMA supplementOct 16, 2026FDA
Foundation Medicine, Inc.PMA supplementSep 18, 2026FDA
Guardant360 CDxP200010/S029
Guardant Health, Inc.PMA supplementSep 18, 2026FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Illumina, Inc.

Headquarters
Not reported
Brand website
illumina.com
FDA applicant address
5200 Illumina Way, San Diego, CA, 92122

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records